BR112013028820A2 - alimento medicinal para declínio cognitivo - Google Patents

alimento medicinal para declínio cognitivo

Info

Publication number
BR112013028820A2
BR112013028820A2 BR112013028820A BR112013028820A BR112013028820A2 BR 112013028820 A2 BR112013028820 A2 BR 112013028820A2 BR 112013028820 A BR112013028820 A BR 112013028820A BR 112013028820 A BR112013028820 A BR 112013028820A BR 112013028820 A2 BR112013028820 A2 BR 112013028820A2
Authority
BR
Brazil
Prior art keywords
cognitive decline
medicinal food
medicinal
food
fisetin
Prior art date
Application number
BR112013028820A
Other languages
English (en)
Inventor
r schubert David
M Cole Greg
A Maher Pamela
A Frautschy Sally
Original Assignee
Us Dept Veterans Affairs
Salk Inst For Biological Studi
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Dept Veterans Affairs, Salk Inst For Biological Studi, Univ California filed Critical Us Dept Veterans Affairs
Publication of BR112013028820A2 publication Critical patent/BR112013028820A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

resumo patente de invenção: "alimento medicinal para declínio cognitivo". a presente invenção refere-se a formulações nutracêuticas que melhoram a função cognitiva em adultos diagnosticados com doença neurodegenerativa que são providas, que compreendem uma combinação de fisetina e dha.
BR112013028820A 2011-05-19 2012-05-18 alimento medicinal para declínio cognitivo BR112013028820A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161488003P 2011-05-19 2011-05-19
PCT/US2012/038720 WO2012159092A2 (en) 2011-05-19 2012-05-18 Medical food for cognitive decline

Publications (1)

Publication Number Publication Date
BR112013028820A2 true BR112013028820A2 (pt) 2017-01-31

Family

ID=47177663

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028820A BR112013028820A2 (pt) 2011-05-19 2012-05-18 alimento medicinal para declínio cognitivo

Country Status (11)

Country Link
US (1) US9254280B2 (pt)
EP (1) EP2709611A4 (pt)
JP (1) JP2014515928A (pt)
KR (1) KR20140057485A (pt)
CN (1) CN103732223A (pt)
AU (1) AU2012254988A1 (pt)
BR (1) BR112013028820A2 (pt)
CA (1) CA2833219A1 (pt)
IL (1) IL229108A0 (pt)
MX (1) MX2013013512A (pt)
WO (1) WO2012159092A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682048B1 (en) * 2010-10-12 2017-06-20 Gene S. Rosen Multi-component formulations for the treatment of cognitive decline including Alzheimer's disease
FR3005419B1 (fr) 2013-05-13 2015-09-04 Agronomique Inst Nat Rech Utilisation d'une association de deux composes pour le traitement et/ou la prevention de troubles osseux
US10183053B1 (en) 2017-06-19 2019-01-22 Gene S. Rosen Multi-component formulations
CA3069352A1 (en) 2017-07-26 2019-01-31 Vincent YACYSHYN Removing polyphenol contaminants from feedstock-based polyphenols
CN108272791A (zh) * 2018-03-26 2018-07-13 深圳大学 漆黄素在制备抑制Tau蛋白异常聚集的药物中的应用
US11173187B2 (en) 2018-11-13 2021-11-16 Immortazyme Company Ltd. Concentrated oil-based polyphenol composition and a method of producing the oil-based polyphenol composition
US20220133700A1 (en) * 2020-10-29 2022-05-05 Thomas Winston Compositions and methods for treating neurological disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
EP2140863A1 (en) * 1993-06-09 2010-01-06 Martek Biosciences Corporation Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders
KR100726266B1 (ko) * 2005-11-24 2007-06-08 (주) 디지탈바이오텍 플라보노이드계 화합물을 함유하는 인지기능 장애의 예방및 치료용 조성물
KR20090107607A (ko) 2008-04-10 2009-10-14 경북대학교 산학협력단 피세틴을 포함하는 퇴행성 신경질환의 예방 또는 치료를위한 약학적 조성물
US20100021573A1 (en) * 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
CA2751275A1 (en) 2009-02-02 2010-08-05 Martek Biosciences Corporation Use of docosahexaenoic acid in treating mild cognitive impairment

Also Published As

Publication number Publication date
JP2014515928A (ja) 2014-07-07
WO2012159092A2 (en) 2012-11-22
CA2833219A1 (en) 2012-11-22
AU2012254988A1 (en) 2013-10-17
US9254280B2 (en) 2016-02-09
KR20140057485A (ko) 2014-05-13
CN103732223A (zh) 2014-04-16
IL229108A0 (en) 2013-12-31
EP2709611A4 (en) 2014-10-29
MX2013013512A (es) 2014-06-05
EP2709611A2 (en) 2014-03-26
US20140142172A1 (en) 2014-05-22
WO2012159092A3 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
BR112013028820A2 (pt) alimento medicinal para declínio cognitivo
BR112015027281A8 (pt) usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores
BR112014030009A2 (pt) polipeptídeos que têm atividade de transgalactosilação
BR112015001884A2 (pt) composição nutricional para promover a saúde musculoesquelética em pacientes com doença inflamatória intestinal (ibd)
BR112015021495A2 (pt) fabricação contínua integrada de substâncias de droga de proteína terapêutica
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112016001950A2 (pt) Glicosídeos de esteviol
BR112015014253A2 (pt) produtos de higiene bucal que compreendem um complexo de haleto de aminoácido e zinco tetrabásico
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112013031268A8 (pt) polipeptídeos
HK1199220A1 (en) Pharmaceutical composition for the prevention or treatment of non- alcoholic fatty liver disease
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
BR112014004726A2 (pt) combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
BR112012032816A2 (pt) composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz
BR112013028705A2 (pt) cepas bacterianas probióticas e composição simbiótica contendo as mesmas destinadas a alimentos para lactentes
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
BR112015006731A2 (pt) combinações e usos das mesmas
CR20140342A (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos hepáticos
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
BR112014032759A2 (pt) composições lipídicas de racecadotril
BR112014001404A2 (pt) produto para a nutrição parenteral de pacientes de tratamento intensivo obesos
BR112013018298A2 (pt) compostos para a redução da produção de beta-amiloides

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]